SUN PHARMACEUTICAL FY26 GUIDANCE

Mid-to-high single-digit top-line growth. It is lower than before because of higher global uncertainty (MFN, tariffs, FX volatility) FY26E R&D at 6-8% of sales (includes existing and new projects both) Expecting $100 mn additional spend for commercialisation of new specialty products